on adrenocortical and thyroid function, and its effect on the urinary excretion of nitrogen. Ten dwarfed patients were selected for study. They were kept on a constant diet, previously determined by the consideration of the patient's appetite and taste and maintained throughout the period of the experiment. Any endocrine, or anticonvulsive therapy, was either given throughout the investigation or had been stopped at least two months before the experiment began. The pre-treatment period lasted from 5 to 9 days, the HGH period from 5 to 9 days, and in 7 patients the observations were continued for 2 to 7 days after HGH had been withdrawn. The HGH was supplied by the Medical Research Council* and had been prepared by the Raben method of extraction from human pituitaries.
Details of the methods are given in Appendix I. The 10 patients who entered this study were all of short stature and all of them had been under observation for many years. They had been submitted to various endocrine investigations. The diagnoses in the 10 patients together with a brief clinical summary are given in Appendix II.
(All measurements of maturation refer to the time of the trial and insulin was administered intravenously in a dose of 0-1 unit/kg. body weight except in Case 2.)
Organic hypopituitarism (Cases 1, 2, and 3).
The hypopituitarism in these three patients was the result of tuberculous meningitis, perinatal brain damage (presumed), and intrasellar craniopharyngioma (presumed) respectively.
Idiopathic hypopituitarism (Cases 4, 5, and 6). These three patients were all grouped together since their hypopituitarism was of unknown aetiology. It appeared improbable that they shared a common pathogenesis. Case 4 presented as a cretin in infancy but her growth failed to respond to adequate thyroid, thyroxine, and triiodothyronine therapy. She had mild spontaneous hypoglycaemic attacks. The sella turcica was tiny (12-5 sq.mm. The straight radio-immuno-assay of growth hormone (GH) appears unlikely to be of great help either in the diagnosis of hypopituitarism or in the differential diagnosis of short stature. The response of GH to insulin-induced hypoglycaemia (Hunter and Greenwood, 1964) promises to be of greater diagnostic value. Our experience with this investigation is increasing and will be the subject of a separate report. There are obvious difficulties in its application to young children and doubtful results may be obtained (Kaplan, Abrams, Bell, Conte, and Grumbach, 1965 Of these 10 children, 7 showed a depression of the levels of the serum cholesterol on HGH with a rebound on withdrawal ( Table I ). The five children who had levels above 200 mg. in the resting fasting state showed an average reduction of 57 mg./ 100 ml. in the HGH period and an average rise of 52 mg./100 ml. during the withdrawal period (Fig. 1) .
The children who showed this fall and rebound in cholesterol included both hypopituitary and nonhypopituitary dwarfs. 3 children showed a rise in cholesterol levels during the HGH period; and of these 2 were on thyroxine therapy (Cases 2 and 4). The third was the boy (Case 6) who had been confidently diagnosed as suffering from idiopathic hypopituitarism but who never showed any hypercholesterolaemia: during the past two years there has been some evidence of depressed thyroid and adrenocortical function (see later).
It may be concluded that in the majority of our patients and in the doses used HGH depresses the level of blood cholesterol with a rebound after withdrawal of HGH. While this fall in the blood cholesterol is a specific effect of HGH, it is not specific for hypopituitarism. Indeed it occurred in a cretin who was given 10 mg. of HGH for 4 days. The cholesterol was 705 mg./100 ml. before HGH was given and it fell to 412 mg./100 ml. by the end of the HGH period. In a further month of thyroxine therapy the cholesterol had returned to Fasting Free Fatty Acids None of our 10 patients-including those with hypopituitarism-had fasting resting FFA's below normal levels. After a fast prolonged to 16 hours in 6 patients, the level of fasting FFA's increased in all of them. The normal fasting resting levels of FFA's in our 6 hypopituitary patients can be held to confirm the observations of Dole, Bierman, and Roberts (1957) that control ofthe blood concentration of fatty acids proceeds normally in man even in the presence of hypopituitarism.
Response to a Fat Load In 6 of the 9 patients who were given a fat meal of 2 g. animal fat per kg. body weight the blood was cleared of fat more slowly (9 hours and beyond) during the HGH period. This effect was also shown in non-hypopituitary as well as in hypopituitary patients.
Production of Pre-P Lipid
Pre-5 lipoprotein, as detected by paper electrophoresis, appeared in the fasting state in our 10 patients during the 6-9 days of HGH treatment. It had not been present in sufficient quantity to be detected by this method in the control period. Earlier studies in our laboratory revealed that the presence of a marked pre-5 band on paper electrophoresis corresponded to a very low density fraction (Sf 15-100) in excess of 125 mg. lipid/100 ml. serum, as measured by the ultracentrifuge (Pantelakis, Fosbrooke, Lloyd, and Wolff, 1964 (1961) suggested that the relative quantities of these f3-r.-.
iipoprotein fractions produced by the liver were, in part, influenced by the amount of FFA's circulating. High FFA levels result in increased hepatic uptake and, by conversion to triglyceride, stimulate the production of pre-3-lipoprotein. This is apparently formed at the expense of 'true' 5-lipoprotein.
These lipid studies will be the subject of a report by the investigators concerned in the research (Fosbrooke, Wolff, Lloyd, Chance, and Albutt) . Our present objective is further to define by ultracentrifuge studies the quantitative and qualitative changes in lipid metabolism of HGH given in short term, high dosage.
Effect of HGH on Pituitary Target Hormones
There are some hypopituitary patients in whom failure of thyroid or adrenocortical function can be detected in the first few years of life: these include children suffering from perinatal brain damage (as in Case 2) and also children of the idiopathic type who show no evidence of brain damage (as in Case 4). In some patients who have been diagnosed with fair confidence as suffering from idiopathic hypopituitarism, there is in the second decade of life evidence of partial failure of thyroid or adrenocortical function or of both. This is evidenced by Case 6, a boy now aged 15 years, who, in the past two years, has shown some defect in the function of thyroid and adrenal cortex. The serum PBI has on several occasions been below 3 5 ,ug./100 ml. and the 132I uptake is 12% at 60 and 90 minutes. Both values have demonstrated a normal response to TSH. Thyroxine therapy has produced no increased velocity of linear growth. The plasma cortisol was 4-4 ,ug./100 ml. and showed a delayed response to corticotrophin stimulation. There was no increase of urinary 17-hydroxycorticosteroids on the second day of the metyrapone test, but the degree of inhibition (25%) of 1 1-l-hydroxylase activity was below our required standard (30%), as estimated by the ratio of tetrahydro-S (THS) to 17-hydrocorticosteroid (17HCS) output in the urine.
This sort of partial failure of target hormones could be the direct consequence of HGH deficiency, and it was interesting to see whether HGH in shortterm high dosage had any recognizable effect on either thyroid or adrenocortical function. 3 patients were tested for thyroid function by serum PBI and radioiodine uptake tests before and during HGH therapy, and no significant difference was detected. Neither were significant differences observed in the urinary steroid patterns nor in the level of the plasma cortisol during HGH administration.
The possibility that a deficiency of endogenous HGH does indeed slowly impair the function of the target organs is not necessarily denied by these short-term experiments.
HGH Nitrogen Retention Test
Estimations of urinary nitrogen were made throughout the control and HGH periods in 10 patients and in the withdrawal period in 7 patients. The nitrogen in each day's urine was separately estimated and the results averaged for each period. These results are given in Table II and Fig. 2 .
The results are also given in terms of nitrogen retention, expressed as a percentage increase or decrease of the pre-HGH nitrogen excretion in the HGH and withdrawal periods. These percentages are given in Table III and graphically in Fig. 3 . The 6 hypopituitary children (Cases 1-6) showed a sharp fall in nitrogen excretion in the HGH period which, estimated as increased nitrogen retention, showed a percentage increase varying from 30 to 470o. The 3 non-hypopituitary dwarfs (Cases 7, 8, 10) showed very little diminution of nitrogen excretion. One patient (Case 9) in whom the diagnosis of hypopituitarism is still uncertain showed The results in the HGH withdrawal period are of considerable interest. The 3 hypopituitary children had not returned to their pre-HGH level of nitrogen excretion in 2, 4, and 5 days, respectively-they were still retaining an increased amount of nitrogen as compared with their control period. The 2 nonhypopituitary dwarfs were excreting more nitrogen in the withdrawal period than in either the pre-HGH or the HGH periods. Case 7 lost 12 6 g. and Case 8 15 -9 g. more nitrogen in the 7 days after HGH than they retained in the HGH period.
Case 9, the doubtful hypopituitary patient, had the same output of nitrogen in the post-HGH period of 5 days as in the pre-HGH period of 5 days.
The urinary nitrogen excretion in Case 10, the primordial dwarf, did not change significantly in either period.
The percentage nitrogen retention results in the HGH period, as set out in Table III In considering the nitrogen retention in the withdrawal period in our 7 patients, it appears that the hypopituitary children take several days to return to their pre-HGH level of nitrogen excretion. In them it may be assumed that the administered HGH is still actively causing nitrogen retention.
The two children who showed a large increase in nitrogen excretion in the withdrawal period, despite little nitrogen retention during HGH administration, may be assumed to have experienced a suppression of endogenous GH which lasted for more than a week after withdrawing exogenous HGH. The same 'rebound' phenomenon was observed in two adult 'normals' as described in a Medical Research Council report (1959) .
The primordial dwarf on whom exogenous HGH had little effect on nitrogen excretion may have a resistance to its normal action on nitrogen metabolism. Lipsett, Bergenstal, and Dhyse (1961) The HGH nitrogen retention test requires further application in the investigation of children of short stature. Although it may not sharply differentiate children with partial growth hormone deficiency from children whose short stature is due to other causes, these preliminary results suggest that it will be very useful in doing so, especially when the results are considered in conjunction with the response of GH to hypoglycaemia. The effects on nitrogen excretion following the withdrawal of HGH may be as useful diagnostically as the degree of nitrogen retention in the period of HGH administration.
Prader and his colleagues used HGH in a dose of 2 mg./m.2 body surface-a much smaller dose than our 10 mg. daily. Their dose was sufficient to differentiate hypopituitary children, but it may be that our larger dose is required to produce the suppressive consequences of endogenous hormone, which became evident in the withdrawal period.
We are now standardizing the test in 3 periods of 5 days each.
Summary
Ten dwarfed patients whose short stature was of varying aetiology were studied by investigation of some of the metabolic effects of human growth hormone, 10 mg. being administered daily for a period of 5 to 9 days. The patients were maintained on a constant diet during a preliminary control period, while receiving HGH, and in 7 patients from 2 to 7 days in the post-HGH period. HGH produced a reduction in serum cholesterol, with a rebound on withdrawal, in 7; a delayed clearance of fat from the blood after a fat load in 9; and the appearance of pre-5 lipoprotein in the fasting state, as measured by paper electrophoresis, in all of them. The fall in serum cholesterol and the rebound on withdrawal of HGH has some relevance to the observation that hypercholesterolaemia occurs in some hypopituitary patients even in the absence of hypothyroidism.
No change was observed in tests of thyroid and adrenocortical function during the short-term high dosage administration of HGH.
Hypopituitary patients show a considerable retention of nitrogen on HGH administration, and we have confirmed the work of Prader and his colleagues that this provides a valuable diagnostic test for growth hormone deficiency. The measurement of urinary nitrogen excretion after the withdrawal of HGH also promises to be a useful investigation in the differential diagnosis of short stature. Nitrogen excretion in the withdrawal phase in hypopituitary children returns slowly to its pre-HGH levels; two non-hypopituitary dwarfed children excreted much more nitrogen in the withdrawal period than they retained in the HGH period. One primordial dwarf showed a negligible change in urinary nitrogen excretion both in the HGH and in the post-HGH periods. nine therapy, she failed to achieve the expected velocity of growth, though the metabolic consequences of hypothyroidism were corrected. She had mild hypoglycaemic attacks. There was neither fasting nor non-fasting hypercholesterolaemia. Her height was 38 * 5 in. (98 cm.) (height-age 3 years 6 months), and her bone-age was between 6 years 10 months and 7 years 10 months. The sella turcica was 12 sq. mm. (average for height 52 -5 sq. mm.). The fasting growth hormone level was 1 ,umg./ ml.
Case 5. Aged 11 years 10 months. This boy presented with spontaneous hypoglycaemia in his fourth year. At the age of 6.1 years, his height-age was 3-L years, and his bone-age was 3-1 years. His skeletal maturation was unduly accelerated by the use of a protein anabolic drug, and at the time he entered the study his height-age was 8 years and his bone-age 11 years. His adrenocortical function was normal, but he had evidence of a mild deficiency of thyroid function. There was non-fasting hypercholesterolaemia, but the levels of fasting cholesterol were within normal limits, i.e. below 250 mg./100 ml. There was increased sensitivity to insulin. He had non-fasting hypercholesterolaemia (average 333 mg./100 ml.) and fasting levels ranging from 248 to 296 mg./ioo ml. The thyroid function was normal. The response to a water load was normal, the resting levels of urinary steroids and plasma cortisol were normal, the response to corticotrophin was normal, but the metyrapone test indicated a defective corticotrophin response. The sella turcica measured 70 sq. mm.
(average for height 64-1 sq. mm.). The fasting growth hormone level was 8 umg./ml. and rose during insulininduced hypoglycaemia to 17 ,umg./ml.
Case 9. He presented at 101 years. His birth weight had been 9 lb. (4,082 g.), and there was no evidence of perinatal damage. His short stature was not noticed till he was 3 years of age. There was no family history of short stature. His response in linear growth to methandienone given daily for one year was only moderate.
His height was 47 in. (119 cm.) (height-age 6 years). There was no increased insulin sensitivity and no hypercholesterolaemia, non-fasting or fasting. Thyroid function was normal and the only abnormal result in adrenocortical function was to the metyrapone test which indicated a low adrenocortical reserve. The area of the sella turcica was 50 * 5 sq. mm. (average for height 65 * 7 sq. mm.).
The fasting growth hormone level was 7 ,mg./ml. and there was no rise during insulin-induced hypoglycaemia (blood glucose 22 mg./100 ml. at 20 minutes and 48 mg./ 100 ml. at 30 minutes).
Case 10. This boy presented at 8-years. His birth weight had been 8 lb. 7 oz. (3,826 g.). There was no history of perinatal damage. When he was 6 months old he weighed only 11 lb. 8 oz. (5,216 g.). There was no family history of short stature, neither were there associated physical stigmata, or any evidence of endocrine abnormality. His facies had been described as 'pekinese', but he showed no characteristics of recognized syndromes associated with short stature. His growth curve travelled still further away from the third percentile from the age of 2 to 5 years despite thyroid therapy. Methandienone given for 1 year 9 months produced an acceleration of linear growth and greater increase of skeletal maturation. His height was 45 in. (114 cm.) (height-age 6 years). The area of the sella turcica was 61 -5 sq. mm. (average for height 63 2 sq. mm.). The fasting growth hormone level was 12 pmg./ ml.
